|
Health101.org
presents
HEALTH
EXPERTS URGE FDA TO DENY
SOY PROTEIN / CANCER PREVENTION
HEALTH CLAIM
Scientists say Solae petition omits many studies
indicating soy may cause cancer
July 5, 2004,
WASHINGTON, DC: Researchers at a non-profit nutrition education
foundation in Washington, DC are urging the Food and Drug Administration
to deny a petition that would clear the way for soy products to
claim they prevent cancer. The Weston A. Price Foundation says a
petition by Solae, a manufacturer of soy protein and other processed
soy products, for a FDA health claim is based on misleading research.
Approved health
claims can be used in product labeling and packaging to influence
consumers in making dietary choices. The FDA will make a decision
later this year.
Kayla T. Daniel,
PhD, author of The Whole Soy Story (to be released Fall 2004), noted
that "Solae was highly selective in its choice of evidence
and biased in its interpretations. It omitted many studies that
show soy to be ineffective in preventing cancer, emphasized favorable
outcome in studies when results were mixed and excused results of
a few unfavorable studies that they included to give the illusion
of balance. Most seriously, Solae omitted many well-designed studies
that have suggested that soy protein can contribute to, cause and
accelerate the growth of cancer."
Solae, a joint
venture of Dupont and Bunge, applied for a Soy Protein and Cancer
Health Claim in March 2004. Sally Fallon, President of the Weston
A. Price Foundation, points out that Solae has a strong financial
interest in winning a cancer health claim. "In their petition,"
notes Fallon, "Solae states that since the FDA authorized the
Soy Protein and Coronary Heart Disease Health Claim, per capita
consumption of soy protein increased from 0.78 g/day in 1998 to
2.23 g/day in 2002. Solae predicts that consumption of soy protein
will double with a cancer health claim. Solae stands to reap tremendous
financial gain at the expense of the public."
"Numerous
experts - including scientists from the FDA's own National Laboratory
for Toxicological Research - have warned of soy protein's carcinogenic
potential and of the health dangers of excess soy-food consumption,"
says Bill Sanda, Director of Public Affairs for the Weston A. Price
Foundation. "Yet in its petition, Solae contends that their
data 'establish that there is scientific agreement among experts
qualified by scientific training and experience to evaluate such
claims regarding the relationship between soy protein products and
a reduced risk of cancers.' No such consensus exists. The British
Committee on Toxicity (COT) reviewed much of the evidence and found
the results to be both 'inconsistent and contradictory.'"
The British
Committee on Toxicity (COT) has stated that "the epidemiological
data on soy intake and prostate cancer are inconsistent" and
that concentrations used in animal experiments are "very high
compared with the likely dietary exposure levels in humans."
These studies not only show that soy foods are not protective against
prostate cancer or less effective than other dietary agents, but
also that soy protein - and its constituent isoflavones - have been
linked to increased prostate cancer risk. In addition, they have
caused undesirable side effects, including changes to the brain.
According to
the Weston A. Price Foundation, Solae also failed to present theories
about why soy might be protective against the development of prostate
cancer. "Prostate cancer is generally thought to be dependent
on exposure to male reproductive hormone. If soy confers protection,
it does so by altering endogenous hormone concentrations - by decreasing
testosterone and androgen levels and feminizing men," said
Fallon. "While this might have valid pharmaceutical applications
for cancer treatment, it seems inadvisable as a preventive treatment
for our entire population of men and boys."
Solae's claim
that soy protein prevents gastrointestinal cancer is contradicted
by numerous studies, including one that links soy protein with a
lowered risk of stomach cancer but a higher risk of colorectal cancer.
Dr. Daniel adds that "Solae also omitted key studies that link
the soy lectin - a component of soy protein - to precancerous conditions
in the small intestines, including shortened villi, a diminished
capacity for digestion and absorption, cell proliferation in the
crypt cells, interference with hormone and growth factor signaling
and unfavorable population shifts among the microbial flora."
Solae states
that "the totality" of the evidence supports a soy protein/cancer
claim, a conclusion that Solae's consultants were able to reach
only through a series of statistical studies known as meta-analyses.
"Meta-analyses serve researchers - and their industry sponsors
- when they wish to draw specific conclusions," explains Fallon.
"Meta-analysts have been criticized by many in the scientific
and statistical communities for making faulty assumptions, indulging
in creative accounting and for leaving out studies that contradict
or dilute the conclusions desired. Solae has left out many such
studies."
Experts were
also concerned about Solae's summaries of the body of evidence concerning
soy and other cancers. Solae chose to minimize a large-scale study
linking soy protein to bladder cancer and it omitted evidence linking
soy protein to thyroid and pancreatic cancers and to childhood leukemia.
Solae also failed to address soy protein's well-documented risks
to the digestive, immune and neuroendocrine systems of the body,
including strong evidence that dietary soy has contributed to rising
rates of infertility and hypothyroidism. Soy is also highly allergenic.
Most experts now place soy protein among the top eight allergens,
and some rate it in the top six or even top four. Allergic reactions
to soy range from mild to life threatening and fatalities have been
reported in medical journals.
Back
to list of Articles
|
Home | Healthful
Products | Articles
| Classes
| Booklist
| Links | Contact
Us |
|